New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSermorelin vs Pancragen

Sermorelin vs Pancragen

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesAnti-Aging & Longevity
Sermorelin
Anti-Aging & Longevity
Pancragen
Summary
Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
10–20 minutes
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
200–500 mcg
10 mg per day
Frequency
5–7 days per week
Daily for 10–30 days
Key Benefits
  • Increases energy and vitality
  • Improves body composition (more muscle, less fat)
  • Enhances skin thickness and elasticity
  • Strengthens immune system
  • Improves sleep quality and REM sleep
  • Supports bone density
  • Enhances mental clarity and focus
  • Safer than exogenous HGH — respects natural feedback loops
  • FDA-approved for GH diagnostic use
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
Side Effects
  • Injection site irritation
  • Flushing
  • Headache
  • Dizziness
  • +2 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
Stacks With